Venous thromboembolism in hospitalized patients receiving chemotherapy for malignancies at Japanese community hospital: prospective observational study

Table 5 Univariable analysis of risk factors for newly developed VTE of 12 patients in three-month observation period

Variable	No. of patients		% per three months	OR	(95% CI)	P
Sex and age (yr.)
< 70	7	/64	11	1.0	(ref.)
≥ 70 male	1	/19	5	0.5	(0.05–3.9)	0.67
≥ 70 female	4	/14	29	3.3	(0.80–13.2)	0.10
BMI
< 25	6	/74	8	1.0	(ref.)
≥ 25	6	/23	26	4.0	(1.2–14.0)^a	0.030^*
Reduced mobility^b
No	11	/87	13	1.0	(ref.)
Yes	1	/10	10	0.8	(0.1–6.7)	1.00
Previous chemotherapy
No	9	/78	12	1.0	(ref.)
Yes	3	/19	16	1.4	(0.4–5.9)	0.70
Time from cancer onset (mo.)
< 6 or >12	7	/85	8	1.0	(ref.)
6–12	5	/12	42	8.0	(2.0–31.8)^a	0.006^*
Central venous access device
No	0	/7	0	1.0	(ref.)
Yes	12	/90	13	2.4	(0.1–44.5)	0.59
Using anti-VEGF antibody
No	11	/80	14	1.0	(ref.)
Yes	1	/17	6	0.4	(0.1–3.3)	0.69
Distant metastases
No	3	/32	9	1.0	(ref.)
Yes	9	/65	14	1.6	(0.4–6.2)	0.75
Developing acute infection^c
No	24	/67	56	1.0	(ref.)
Yes	5	/30	20	0.4	(0.1–1.1)	0.10
Platelet count (/μL)^d
< 350,000	12	/87	12	1.0	(ref.)
≥ 350,000	0	/10	0	0.3	(0.0–5.2)	0.60
Hemoglobin (g/dL)^d
≥ 10	10	/84	12	1.0	(ref.)
< 10	2	/13	15	1.4	(0.3–7.0)	0.66
Leukocyte count (/μL)^d
< 11,000	12	/93	13	1.0	(ref.)
≥11,000	0	/4	0	0.7	(0.0–14.3)	1.00
D-dimer (μg/mL)^{d, e}
<1.5	3	/36	8	1.0	(ref.)
≥1.5	7	/58	12	1.5	(0.4–6.3)	0.74
TAT (ng/mL)^{d, e}
< 2.1	2	/50	2	1.0	(ref.)
≥ 2.1	8	/44	18	5.3	(1.1–26.6)^a	0.042^*
PIC (μg/mL)^{d, e}
≥ 1.8	0	/21	0	1.0	(ref.)
< 1.8	10	/73	14	7.1	(0.4–126.5)	0.11
TAT ≥2.1 ng/mL and PIC <1.8 μg/mL^{d, e}
No	2	/65	3	1.0	(ref.)
Yes	8	/29	28	12.0	(2.4–61.0)^a	0.001^*

ISSN: 1471-2407